Description: Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Home Page: www.aptevotherapeutics.com
APVO Technical Analysis
2401 4th Avenue
Seattle,
WA
98121
United States
Phone:
206 838 0500
Officers
| Name | Title |
|---|---|
| Mr. Marvin L. White | Pres, CEO & Director |
| Mr. Jeffrey G. Lamothe CA | Exec. VP & CFO |
| Dr. Jane A. Gross Ph.D. | Chief Scientific Officer |
| Ms. SoYoung Kwon J.D., LL.M. | Sr. VP, Gen. Counsel, Corp. Affairs & HR |
| Dr. Fatih M. Uckun M.D., Ph.D. | Chief Clinical Advisor & Consultant |
| Dr. Dirk Huebner M.D. | Chief Medical Officer |
| Ms. Daphne L. Taylor | Sr. VP of Fin. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 3.9448 |
|---|---|
| Trailing PE: | 1.9706 |
| Price-to-Book MRQ: | 0.8141 |
| Price-to-Sales TTM: | 1.6074 |
| IPO Date: | 2016-07-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 54 |